A New Approach to Interstitial Lung Disease J.P. Morgan Healthcare Conference Sanjay S. Shukla, M.D., M.S., President and CEO January 16, 2025 Forward Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "f ...

SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company is expected to be added to the Russell 2000® Index and broad market Russell 3000® Index, effective after the U.S. market close on June 27, 2025, as part of the 2025 Russell U.S. Indexes annual reconstitution. The Russel ...

aTyr Pharma (ATYR) 2025 Conference June 05, 2025 02:00 PM ET Speaker0 Alright. Welcome, everyone, to twenty twenty five Jefferies Global Healthcare Conference. My name is Roger Song, one of the senior that covers SMICHA biotech at Jefferies, in The US. It's my pleasure to have the next fireside chat with entire pharma CEO Sanjay. Good afternoon, Sanjay. Speaker1 Hi, Roger. How are you? Speaker0 Very good. Alright. So, why not we just get right in, into your lead program, for the pulmonary sarcoidosis? I kno ...

Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well tolerated at all doses. SAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in- class medicines from its proprietary tRNA synthetase platform, today announc ...

Summary of Atyre Pharma Conference Call Company Overview - Atyre Pharma is positioned as a leading company in the interstitial lung disease sector, focusing on the development of therapies for conditions such as pulmonary sarcoidosis with its lead program, esofitimod [4][5] Key Points and Arguments Upcoming Phase Three Catalyst - Atyre Pharma is anticipating a major phase three trial readout for esofitimod in pulmonary sarcoidosis, which could be the first new therapy for this condition in 70 years [4][5] - The company has transitioned esofitimod through various stages of development, culminating in a highly derisked asset ready for pivotal trials [5] Data-Driven Approach - Atyre emphasizes a data-driven methodology, showcasing significant preclinical and phase two data that supports the efficacy of esofitimod in modulating immune responses without the heavy immunosuppressive effects typical of existing treatments [6][7][9] - The company has published extensively, including in high-impact journals, to validate its findings and maintain transparency with investors [12][14][15] FDA Interaction and Endpoint Adjustments - Recent discussions with the FDA have led to a refined approach to analyzing steroid reduction as a primary endpoint, which is now expected to yield more favorable statistical outcomes [18][19][22] - The FDA's guidance has allowed Atyre to adjust its statistical model positively, potentially lowering the threshold for demonstrating statistical significance [19][22] Market Potential and Demographics - Atyre's updated epidemiological work indicates that the steroid-dependent population for sarcoidosis is larger than previously estimated, now believed to be around 75% of the 200,000 patients in the U.S. [44][45] - The potential market opportunity for esofitimod is now projected to be between $5 billion to $6 billion, significantly higher than earlier estimates [46] Clinical Trial Insights - The trial involves a diverse patient population across 90 centers in nine countries, with baseline demographics aligning closely with previous studies [30][31][34] - The company has taken steps to ensure data integrity and quality, which is crucial for the pivotal submission [39] Future Indications and Pipeline - Atyre is exploring additional indications for esofitimod, including scleroderma ILD, although the readouts from this trial are not expected to directly influence the sarcoidosis data [50][53] - The company has introduced a new IND program targeting myofibroblast apoptosis, which could have significant implications for treating idiopathic pulmonary fibrosis (IPF) [58][60] Other Important Content - The company has received positive feedback from the medical community regarding its innovative approach to treating sarcoidosis, with many expressing gratitude for the efforts to reduce steroid dependency [10][26] - Atyre's commitment to rigorous clinical trial design and data publication is highlighted as a key differentiator in the biotech space [12][15] This summary encapsulates the critical insights and developments discussed during the conference call, reflecting Atyre Pharma's strategic direction and market positioning.

In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the RBC and Jefferies conferences. A webcast of the RBC and Jefferies events will be available on the Investor's section of the company's website at www.atyrpharma.com. Following the events, a replay of the RBC and Jefferies presentations will be available on the aTyr website for at least 90 days. For more information, contact investorrelations@atyrpharm ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdiction ...

Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be present ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be presented at ATS 2025. SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-i ...

Core Insights - aTyr Pharma, Inc. is presenting preclinical data for ATYR2810, a monoclonal antibody targeting neuropilin-2 (NRP2), at the AACR Annual Meeting 2025, indicating progress in its clinical development [1][2] Group 1: Company Overview - aTyr Pharma is a clinical stage biotechnology company focused on developing first-in-class medicines from its proprietary tRNA synthetase platform [1][4] - The company's lead therapeutic candidate is efzofitimod, which is in clinical development for treating interstitial lung disease [4] Group 2: Research Findings - ATYR2810 has shown potential in combating drug resistance mechanisms in aggressive cancers like glioblastoma multiforme (GBM) [2][3] - Preclinical research indicates that ATYR2810 enhances anti-tumor immunity and significantly increases overall survival when used as a single agent [3] - The combination of ATYR2810 with anti-PD-1 therapies further improves survival rates and reduces tumor size in GBM models [3]